Clinical Trials
47 trialsFASCINATE-N
Fudan University
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
BARBICAN
Queen Mary University of London
TARMAC
University College Hospital, Ibadan
NeoTRACT
University of Kansas Medical Center
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Virginia Commonwealth University
NeoSACT
Guangdong Provincial People's Hospital
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
M.D. Anderson Cancer Center
PRISM-TNBC
Shandong Cancer Hospital and Institute
MK-5890-003
Merck Sharp & Dohme LLC
TARMAC
University of Chicago
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
University of Wisconsin, Madison
Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Dana-Farber Cancer Institute
neoMono
Palleos Healthcare GmbH
AZALEA
European Institute of Oncology
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
University of Nebraska
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Vanderbilt-Ingram Cancer Center
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
Massachusetts General Hospital
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
NeoADAPT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer
University of Illinois at Chicago
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Thomas Jefferson University
RESPONSE
Baylor Breast Care Center
TNBC
ImmunityBio, Inc.
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
M.D. Anderson Cancer Center
ALICE
Oslo University Hospital
NeoTENNIS
Fudan University
KEYPARTNER
Fundacao Champalimaud
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
G1 Therapeutics, Inc.
Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
West China Hospital
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
Barbara Ann Karmanos Cancer Institute
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
Academic and Community Cancer Research United
HIFU
The First Affiliated Hospital with Nanjing Medical University
Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer
Jilin University
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer
Sun Yat-sen University
NeoSTOP
University of Kansas Medical Center
NIB
Institut fuer Frauengesundheit
Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)
Shandong Cancer Hospital and Institute
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
ChineseAMS
GeparOla
GBG Forschungs GmbH
Phase II ABT-888 With Cyclophosphamide
National Institutes of Health Clinical Center (CC)
META2
Centre Jean Perrin
Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer
Russian Academy of Medical Sciences
Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer
Russian Academy of Medical Sciences